Importantly, MDM2 amplification in tumor cells has recently been suggested as a potential biomarker for HPD that is observed in some patients (5–29%) after ICI therapy, suggesting a potential role of MDM2 overexpression in cancer cell immune evasion3,4. This evidence concerns the gene MDM2 and neoplasm.